Two late-stage studies funded by ViiV Healthcare and GlaxoSmithKline compared the two-drug HIV regimen of dolutegravir plus Dovato, or lamivudine, to the three-drug treatment of dolutegravir plus tenofovir and emtricitabine in treatment-naive patients and were able to establish that the two-drug regimen was non-inferior at 96 weeks. Data from the study were presented during the International AIDS Society Conference on HIV Science.
Studies show two-drug HIV regimen noninferior to three-drug therapy
Sign up for AIChE SmartBrief
News for chemical engineers
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.